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We identified a novel human AMP-activated protein
kinase (AMPK) family member, designated ARK5, en-
coding 661 amino acids with an estimated molecular
mass of 74 kDa. The putative amino acid sequence re-
veals 47, 45.8, 42.4, and 55% homology to AMPK-1,
AMPK-2, MELK, and SNARK, respectively, suggesting
that it is a new member of the AMPK family. It has a
putative Akt phosphorylation motif at amino acids 595–
600, and Ser600 was found to be phosphorylated by active
Akt resulting in the activation of kinase activity toward
the SAMS peptide, a consensus AMPK substrate. During
nutrient starvation, ARK5 supported the survival of
cells in an Akt-dependent manner. In addition, we also
demonstrated that ARK5, when activated by Akt, phos-
phorylated the ATM protein that is mutated in the hu-
man genetic disorder ataxia-telangiectasia and also in-
duced the phosphorylation of p53. On the basis of our
current findings, we propose that a novel AMPK family
member, ARK5, is the tumor cell survival factor acti-
vated by Akt and acts as an ATM kinase under the con-
ditions of nutrient starvation.
AMPK1 is a mammalian homologue of sucrose non-ferment-
ing protein kinase (SNF-1), which belongs to a serine/threonine
protein kinase family, and its activation is well documented in
cells under metabolic stress, hypoxia, heat shock, and ischemia
(1, 2). The SNF-1/AMPK family is highly conserved in several
species including mammals (3–8), and the -subunit of AMPK
has been shown to be the catalytic subunit (2). Four proteins,
AMPK-1 and AMPK-2 (9–12), MELK (5), and SNARK (13),
have been identified as catalytic subunits of the AMPK family
to date. Although it has been reported that AMPK activation is
initiated by phosphorylation at Thr172 (14), how the phospho-
rylation is initiated remains unclear.
AMPK is activated under various stress conditions where the
cellular ATP concentration decreases and plays a key role in
cellular adaptive responses to maintain energy balance. The
well known targets of AMPK belong to those involved in energy
metabolism including 3-hydroxy-3-methylglutaryl coenzyme A
reductase (HMG-CoA), acyl-CoA decarboxylase, and glucose
and amino acid transporters (15). However, the cellular mech-
anism for survival under stress conditions is complex and in-
cludes cell cycle regulation, repair of cellular components, re-
modeling tissue components, and regulation of the cell death
pathway. Targets of AMPK are not fully described to date.
Recently, we demonstrated that some tumor cells, such as the
pancreatic cancer cell line PANC-1, showed high tolerance
against glucose starvation, which is compatible with hypovas-
cular findings on clinical angiography (16), although most cell
lines, including a human hepatoma cell line and the human
normal fibroblast cell line, underwent cell death under glucose
starvation (16, 17). Similar tolerance to glucose starvation was
induced by hypoxic conditions, and tolerance was found to be
dependent on AMPK activity as well as Akt (16–18). During
glucose starvation, a G1 phase cell cycle delay occurs with a
concomitant increase in p53 phosphorylation, and AMPK ap-
peared to be involved in this process (19).
The tumor suppressor gene ATM has been identified as the
gene defective in the human genetic disorder ataxia-telangiec-
tasia, which is characterized by neurological degeneration and
cancer predisposition (20–22). ATM is a member of the phos-
phatidylinositol 3-kinase family that activates the tumor sup-
pressor p53 during the cellular response to DNA double strand
break (23–25). Although several studies have reported a close
involvement of the ATM/p53 pathway during the cellular re-
sponse to DNA damage, the regulation of this pathway, partic-
ularly by non-DNA damage events, has not been well de-
scribed, and it remains unclear how ATM is activated.
In the current study, we identified a novel AMPK family
member through an investigation of human SNARK and des-
ignated it ARK5. ARK5, the activation of which was observed
during glucose starvation, caused cells to survive in an Akt-de-
pendent manner. Furthermore, Akt-activated ARK5 phospho-
rylated ATM both in vivo and in vitro and led to the phospho-
rylation of p53. We report here that a novel AMPK family
member, ARK5, is a new target molecule of Akt and transduces
a signal to activate ATM during nutrient starvation.
EXPERIMENTAL PROCEDURES
Preparation of FLAG-tagged ARK5—FLAG-tagged ARK5 was pre-
pared from full-length KIAA0537-ligated pBluescript II SK vector
supplied from KAZUSA DNA Research Institute with LA PCR (Takara
Biomedicals, Kyoto, Japan); the up-stream primer was 5-AAGCTTAT-
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GGATTATAAAGATGATGATGATAAAGAAGGGGCCGCCGCGCCTG-
TGGCGGGG-3 and the down-stream primer was 5-TCTAGACTAGT-
TGAGCTTGCTGCAGATCTCCAG-3. The PCR product was ligated
into pT7-Blue T vector for subcloning, and then insert cDNA digested by
HindIII and XbaI was re-ligated into the pcDNA3.1() expression vec-
tor. Insert cDNA was also ligated into pcDNA3.1() expression vector
for the preparation of antisense RNA expression vector.
The FLAG-ARK5 protein was prepared by immunoprecipitation
technology using anti-FLAG-conjugated agarose. A HepG2 cell line
overexpressing FLAG-ARK5 (H/ARK) was lysed with PBS containing
0.1% Nonidet P-40, and then immunoprecipitation was performed. Im-
munoprecipitates were washed eight times with PBS containing 0.1%
Nonidet P-40, and purification was then examined with SDS-PAGE and
silver staining.
Antibodies and Vectors—Monoclonal antibody against FLAG and
His6, anti-FLAG-conjugated agarose, recombinant active Akt1, and
dominant negative and dominant active Akt1 expression vectors were
purchased from Upstate Biotechnology. Polyclonal antibody against
total Akt and phosphorylated Akt (Ser473) were purchased from Cell
Signaling Technology.
Cell Line and Culture—Cell lines used for current experiments were
maintained in Dulbecco’s modified Eagle’s medium supplemented with
10% fetal calf serum (Sigma). Cell viability was assessed by the Hoechst
33342/PI staining procedure. Hoechst 33342 and PI were purchased
from Molecular Probes. After treatment, cells were collected and
stained with Hoechst 33342 and PI and then observed by fluorescence
microscopy. Cell induction ratio was indicated by the ratio of cells
carrying PI-stained nuclei to total cells (about 1000 cells).
Akt1 Phosphorylation Assay—FLAG-tagged proteins were isolated
from cell lysate by anti-FLAG-conjugated agarose and suspended in
kinase buffer containing 25 mM Tris (pH 7.5), 2 mM dithiothreitol, and
10 mM MgCl2. Subsequently, 100 M [-
32P]ATP (20 Ci) and recombi-
nant active Akt1 were added to a kinase buffer containing recombinant
proteins and incubated for 30 min at 30 °C. After incubation, the aga-
rose was washed six times with PBS containing 0.1% Nonidet P-40 and
then re-suspended in PBS, and radioactivity was measured with a
scintillation counter. Furthermore, measured samples were separated
on 7.5% SDS-PAGE for autoradiography.
Preparation of Anti-human SNARK Antibody—Antibody to human
SNARK was raised in rabbits by immunizing them against a peptide
based on the predicted amino acid sequence of human SNARK
(KKPRQRESGYYSSPEPS). The peptide was synthesized and coupled
to keyhole limpet hemocyanin (KLH) at the C terminus. Japanese
White rabbits were immunized with 0.5 mg of peptide conjugate by
initially injecting it in 50% Freund’s complete adjuvant (Sigma) and in
50% Freund’s incomplete adjuvant (Sigma) for subsequent immuniza-
tions. One week after the booster injection of 0.5 mg of peptide conju-
gate, polyclonal anti-human SNARK antiserum was collected and used
for immunoblotting analysis.
GST-SAMS Phosphorylation Assay—Crude cell extracts and immu-
noprecipitates were used to assay the phosphorylation of the SAMS
peptide fused to glutathione S-transferase. An enzyme assay was per-
formed at 30 °C in buffer containing 15 mM HEPES (pH 7.0), 200 mM
5-AMP, 200 mM GST-SAMS, cell lysate, 0.01% Briji 35, 0.3 mM dithi-
othreitol, 15 mM MgCl2, and 50 mM [-
32P]ATP (10 mCi). After incuba-
tion, the fusion protein was purified with glutathione-Sepharose (Am-
ersham Biosciences) and counted in scintillation counter (Beckman
Coulter). There was no significant difference in Km value between
SAMS peptide and GST-SAMS.
RESULTS
ARK5 Is the Novel AMPK Family Protein Kinase Leading
Cells to Survival—Recently, a novel AMPK family member,
SNARK, was identified from rat (13). On the basis of the
reported amino acid sequence, BLAST search analysis revealed
a human cDNA encoding SNARK (the amino acid sequence is
listed in Fig. 1B), and we prepared a polyclonal antibody
against the SNARK peptide. Using this antibody, the endoge-
nous expression of SNARK in several human cell lines includ-
ing lung carcinoma (PC-10 and A549), pancreatic cancer
(PANC-1 and ASPC-1), hepatoma (HepG2 and HLE), and fi-
broblast (HF) was examined. As shown in Fig. 1A, Western
blotting revealed the expression of an unknown cross-reacting
protein at 74 kDa in some of cell lines tested (intense expres-
sion in PC-10, PANC-1, ASPC-1 and HLE; weak expression in
A549 and HF; no expression in HepG2). Because the calculated
molecular mass of human SNARK is 69.5 kDa, we tried to
identify this 74-kDa unknown protein by BLAST search anal-
ysis using human SNARK amino acid sequence or the peptide
sequence by which the anti-human SNARK antibody was pre-
pared and a human protein data base, and we found a putative
protein encoded by a KIAA0537 cDNA clone. As shown in Fig.
1B, the putative catalytic domain of SNARK and the KIAA0537
protein showed 84% similarity, and the peptide sequence used
for the preparation of the anti-human SNARK antibody also
showed strong similarity with the KIAA0537 protein. To inves-
tigate whether this KIAA0537 cDNA clone encodes the un-
known 74-kDa protein detected by the SNARK antibody, we
prepared a FLAG-tagged KIAA0537 cDNA. When the cDNA
was expressed in HepG2 cells, Western blotting using mono-
clonal and polyclonal antibodies against FLAG and SNARK
gave a common 74-kDa band, suggesting that KIAA0537 cDNA
encodes the above mentioned unknown 74-kDa protein (Fig.
1C). Because four factors, AMPK-1, AMPK-2, MELK, and
SNARK, have been identified as the catalytic subunits of the
AMPK family (Fig. 1D), we tentatively designated KIAA0537
as ARK5.
Homology search analysis of the ARK5 amino acid sequence
revealed that it has 55.0% overall homology to human SNARK
(data not shown). It also shows 47.0, 45.8, and 42.4% homology
to AMPK-1, AMP-2, and MELK respectively (data not
shown). These data strongly suggest that ARK5 is a serine/
threonine protein kinase activated by AMP. This possibility
was directly examined by transfecting an ARK5 expression
vector into HepG2 cells (H/ARK), which do not otherwise show
any cross-reactivity to anti-SNARK for the 74-kDa band (Figs.
1A and 2A). As shown in Fig. 2A, H/ARK showed a distinct
band at 74 kDa. This was further confirmed by the immuno-
precipitation method. Cellular extracts from parental HepG2
and H/ARK cell lines were immunoprecipitated with an anti-
FLAG antibody first, and both the supernatant and the immu-
noprecipitates were subjected to Western blot analysis using
anti-SNARK antiserum. Only immunoprecipitates from
H/ARK cells gave strong reactivity (Fig. 2A). In vitro kinase
activity showed a clear increase using GST-SAMS as a sub-
strate after transfection. The activity was further stimulated in
the presence of 200 M AMP (Fig. 2B), indicating strongly that
ARK5 is a novel member of the AMPK family. - and -sub-
units of AMPK have been well known as the binding proteins of
AMPK-1 and AMPK-2 (12, 26). In the previous report (13), it
appeared that rat SNARK showed the enzyme activity without
any binding protein. In the current study, immunoprecipitation
and silver staining technologies showed that binding proteins
were not required for the enzymatic activity of ARK5 (data not
shown).
We have proposed that tolerance to nutrient starvation is
one of the determinants of tumor malignancy (16, 18), and
tolerance to glucose starvation can be induced by the activation
of AMPK (18) or the hypoxic condition (17). In this context, the
involvement of ARK5 in the mechanism for tolerance to glucose
starvation was examined. When a human hepatoma cell line,
HepG2, was subjected to glucose starvation under normoxic
(21% O2) conditions, more than 90% of the cells underwent
necrotic cell death during 24 h treatment, but only 40% of
H/ARK cells showed cell death during the same treatment (Fig.
2C). We prepared an antisense RNA expression vector of ARK5
(ARK5(AS)). When HepG2 or PANC-1 cells were transiently
transfected with ARK5(AS), mRNA expression of ARK5 was
specifically suppressed (Fig. 2D). When cells were subjected to
glucose starvation at 1% oxygen tension, 90% of HepG2 cells
survived, but 50% cells died when ARK5(AS) was transfected
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into HepG2 cells (Fig. 2E). These results clearly showed that
ARK5 is involved in tolerance to glucose starvation.
ARK5 activity in whole cell extracts and anti-FLAG immu-
noprecipitates was measured as the GST-SAMS phosphoryla-
tion during glucose starvation. As shown in Fig. 2F, increased
activity was observed in cell extracts and immunoprecipitates
from H/ARK cells but not from HepG2 cells. In addition, more
increased activity was detected when H/ARK cells were sub-
jected to glucose-free medium for 1 h (Fig. 2F).
ARK5 Is Activated by Akt through Phosphorylation at
Ser600—We have previously found that another protein kinase,
Akt, is activated immediately after nutrient starvation in
HepG2 cells (16). As is evident in Fig 3A, Akt was phosphoryl-
ated rapidly. Amino acid sequence analysis of ARK5 revealed
that there is a perfectly conserved putative Akt phosphoryla-
tion site in the C-terminal portion as shown in Fig. 3B. How-
ever, the putative Akt phosphorylation site was not detected in
AMPK-1, AMPK-2, and SNARK (data not shown). These
observations strongly indicate that ARK5 is activated by Akt
through phosphorylation at Ser600. This possibility was directly
examined in vitro. A point mutant of ARK5 at Ser600 was
constructed by substituting Ser with Ala, and an expression
vector with a FLAG tag was constructed (ARK5(S600A)). Both
wild-type and ARK5(S600A) were transfected into HepG2 cells,
and FLAG-tagged ARK5 and ARK5(S600A) were purified by
immunoprecipitation with anti-FLAG antibody-conjugated
agarose. ARK5 phosphorylation was examined after incubation
with or without PDK1-activated Akt1 in vitro. As shown in Fig.
3C, only ARK5 but not ARK5(S600A) was phosphorylated by
Akt. In addition, an increased phosphorylation of GST-SAMS
was induced by ARK5 but not by ARK5(S600A) in the presence
of active Akt1 (Fig. 3D), suggesting that ARK5 phosphorylated
by active Akt1 is enzymatically “active”. To further examine
the activation of ARK5 by Akt, physiological interaction of
these components in vivo was examined by ARK5 and Akt
co-immunoprecipitation. The results clearly showed that ARK5
and Akt were in association with each other, but they dissoci-
ated just after Akt activation either by glucose starvation or
insulin treatment that activates Akt (Fig. 3E), which is con-
sistent with the case of Mdm2 phosphorylation by Akt (27). No
Akt was co-immunoprecipitated from HepG2 cells with anti-
FLAG antibody (data not shown).
To determine whether enzymatic activation of ARK5 is really
required for tolerance to glucose starvation, the effects of trans-
fection of ARK5 mutants and the dominant active and domi-
nant negative forms of Akt as well as the chemical inhibitor of
FIG. 1. Identification of KIAA0537 as ARK5. A, cell extracts from several lines were Western blotted with SNARK antibody. Asterisk shows
the position of an unknown 74 kDa protein. B, putative amino acid sequence of KIAA0537 (top lines) and human SNARK (bottom lines). Box A, the
region of putative catalytic domain. Box B, amino acid sequence used for the preparation of SNARK antibody. C, cell extracts from HepG2
transfected with () or without () an expression vector of FLAG-KIAA0537 were Western blotted with antibody against FLAG (FLAG) or
SNARK (SNARK). D, evolutional tree of molecules belonging to AMPK family.
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Akt activation on HepG2 survival during glucose starvation
were examined. As shown in Fig. 4A, 90% of HepG2 cells
underwent necrotic cell death during 24 h of glucose starvation.
Necrotic cell death was markedly suppressed to 40% by
transfecting wild-type ARK5 but not ARK5(S600A) or
ARK5(APM) (ARK5 lacking 66 amino acids in the C-terminal
region including the Akt phosphorylation site). When dominant
active (DA-Akt), but not dominant negative, (DN-Akt) Akt was
transfected into HepG2, cell death induction was also sup-
pressed significantly. The combined expression of ARK5 and
dominant active Akt suppressed cell death further, down to
20%, but dominant negative Akt and/or mutants of ARK5
failed to do so (Fig. 4A). These results clearly indicated that
ARK5 activated by active Akt is essential for tolerance to
glucose starvation in HepG2 cells. These observations were
further confirmed using H/ARK cells (Fig. 4B). When dominant
active Akt is introduced into H/ARK cells, cell death was re-
markably suppressed (Fig. 4B). However, when dominant neg-
ative Akt was used, induction of cell death occurred to a greater
extent (Fig. 4B). When an inhibitor of phosphatidylinositol-3
kinase, LY294002 (28), was included, activation of Akt was
clearly inhibited with a concomitant increase in cell death.
These results are consistent with those for transient
transfections.
ATM Is a Candidate for Being the Target of ARK5—Tumor
tolerance against nutrient starvation is found to be modulated
by AMPK (18, 29), and AMPK activation induces a G1 cell cycle
delay as a result of p53 stabilization (19). Because ATM is well
known as a p53 activator, we suspected that ATM might be a
target of AMPKs. As shown in Fig. 5A, amino acid sequence
analysis revealed that ATM contains some putative phospho-
rylation sites for Akt (two sites) and AMPK (three sites). Using
the PANC-1 cell in which His-tagged ATM (30) is stably ex-
pressed (P/ATM), an in vivo 32P-labeling study was performed.
32P incorporation into His-ATM was detected in P/ATM cells
cultured in ordinary medium, and an increase in ATM phos-
phorylation was detected when P/ATM cells were subjected to
glucose starvation (Fig. 5B). Interestingly, ATM phosphoryla-
tion was completely suppressed by the transient expression of
an antisense RNA expression vector of ARK5, and an increased
phosphorylation of ATM was detected in cells transiently ex-
FIG. 2. Characterization of ARK5 as an AMPK family member.
A, Western blotting analysis with SNARK antibody was performed on
cell extracts (Ext.) or immunoprecipitates (IP.) with FLAG antibody
(sup., supernatant; ppt., immunopellet) from HepG2 or H/ARK cells. B,
SAMS phosphorylation by cell extracts (HepG2 and H/ARK) or recom-
binant ARK5 (rARK5) was measured in the presence () or absence ()
of 200 M AMP. Enzyme activity is shown as means of three experi-
ments, and the bars represent S.E. value. Asterisks show the statistical
significance p  0.01 (t test). C, cell death induction was measured in
HepG2 or H/ARK cells subjected to medium with () or without ()
glucose for 24 h. Ratio of cell death induction is shown as means of three
experiments, and the bars represent S.E. value. Asterisks show the
statistical significance p  0.01 (t test). D, expressions of ARK5,
SNARK, AMPK-1, and AMPK-2 were examined with the reverse
transcription PCR method to total RNA (0.5 g) from HepG2 (HG) or
PANC-1 (P-1) cell lines transiently transfected with ARK5(AS). E,
HepG2 cells transfected with (filled bars) or without (open bars) ARK5
antisense were subjected to medium with () or without () glucose
under normoxic (21%) or hypoxic (1%) oxygen tension for 24 h. F, SAMS
phosphorylation activity of cell extracts (WCE) or immunoprecipitates
(IP) from HepG2 (HG) or H/ARK (HA) cells cultured in medium with ()
or without () glucose for 1 h was measured. Enzyme activity is shown
as means of three experiments and the bars represent S.E. value.
Asterisks show the statistical significance p  0.01 (t test).
FIG. 3. ARK5 is a novel substrate of Akt. A, cell extracts from
HepG2 or H/ARK cells subjected to glucose starvation for the indicated
periods were Western blotted with polyclonal antibody against phospho
Akt (pAkt) or total Akt (tAkt). B, comparison of Akt phosphorylation
sites in ARK5 and other substrates. C, ARK5 or ARK5(S600A) was
incubated with active Akt1 (act.Akt1) in vitro. After incubation, immu-
noprecipitates with anti-FLAG antibody were separated on SDS-PAGE.
Immunoprecipitate with anti-FLAG antibody from H/ARK cells labeled
with [35S]methionine was also separated on SDS-PAGE. D, ARK5 and
ARK5(S600A) was were incubated with () or without () active Akt1
(act.Akt) in vitro. After incubation, SAMS phosphorylation was meas-
ured. 32P incorporation is shown as means of three experiments, and the
bars represent S.E. value. Asterisks show the statistical significance p
0.01 (t test). E, H/ARK cells were subjected to glucose starvation or
insulin stimulation for 0–60 min, and whole cell extracts (WCE) or
immunoprecipitates with antibody against FLAG (FLAG-IP) or Akt
(Akt-IP) were blotted with antibody for total Akt (tAkt), phospho Akt
(pAkt) or FLAG.
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pressing ARK5 (Fig. 5B), suggesting that ARK5 phosphoryl-
ates ATM during glucose starvation. To further confirm this
possibility, in vitro phosphorylation was examined. As shown
in Fig. 5C, ARK5- or PDK1-activated Akt1 alone did not phos-
phorylate ATM; however, ATM phosphorylation was detected
in the presence of both ARK5 and active Akt1, indicating that
ARK5 phosphorylates ATM directly. To determine that this
phosphorylation of ATM was activating ATM kinase, we as-
sayed for phosphorylation of p53, which has been shown to be
a downstream effector of ATM (23–25). The results in Fig. 5D
reveal that p53 is phosphorylated in the presence of both ATM
and ARK5, suggesting that ARK5-phosphorylated ATM is func-
tionally active. When HepG2 cells were subjected to glucose-
free medium for 1 h, an accumulation of p53 protein was
observed (Fig. 5E). This p53 accumulation induced by glucose
starvation was completely suppressed by the transient trans-
fection of ARK5(AS) (Fig. 5E). These results indicate that
ARK5 activated during glucose starvation induces p53 accu-
mulation through the functional phosphorylation of ATM in
tumor cells.
DISCUSSION
We recently found that some tumor cells have a strong tol-
erance to nutrient starvation; tolerance to glucose starvation
can be induced by hypoxia in normal human fibroblasts and the
human hepatoma HepG2 cells, which are otherwise quite sen-
sitive to glucose starvation. Akt and AMPK appear to be in-
volved closely in the mechanism of tolerance (16–18). Taking
all these findings into consideration, we suspected that there
might be a connection between Akt and AMPK signaling path-
ways. The consensus sequence of the Akt phosphorylation is
conserved in several species. ARK5, but not other members of
AMPK family, contains this sequence at amino acids 595–600,
and direct activation by Akt was demonstrated by phosphoryl-
ation in vitro in this study. This observation strongly indicates
that ARK5 is a novel target of Akt. During glucose starvation,
cell survival was induced by ARK5, and ARK5 mutants blocked
DA-Akt1-induced cell survival, indicating that ARK5 acts as
the tumor cell survival factor down-stream to Akt in HepG2
cells. In previous studies, we found that the antisense RNA
expression constructs for AMPK-1 and AMP-2 subunits sup-
pressed hypoxia-induced tolerance to glucose starvation in
HepG2 cells (17) and constitutive tolerance in PANC-1 cells
(29), indicating a close involvement of AMPK-1 and AMP-2
in tumor cell tolerance during glucose starvation. AMPK-1
appeared to be more responsive to hypoxic conditions than
AMPK-2 (17). In our previous reports (16, 17), we also dem-
onstrated an important role of Akt in tumor cell tolerance
induced by hypoxia. The Akt phosphorylation was suppressed
by the PI3K inhibitor LY294002 and wortmannin, but not by
the AMPK inhibitor AraA (16, 17), suggesting an involvement
of PI3K but not AMPK in the phosphorylation of Akt during
glucose starvation and hypoxia. Because only ARK5 but not
any other member of the AMPK family is responsive to Akt, it
appears that ARK5 acts as the key mediator of Akt in tumor
cell tolerance during glucose starvation. ARK5, the activation
of which is induced by Akt during glucose starvation and hy-
poxia, may influence AMPK-1 and AMPK-2 to induce tumor
cell tolerance to glucose starvation under the hypoxic condition.
Recently, we demonstrated that the AMPK family is involved
in cell cycle arrest via p53 accumulation (19). ATM is a member
of the phosphatidylinositol kinase family (20–22) and in re-
sponse to radiation exposure activates the G1/S checkpoint via
p53 phosphorylation (23, 24). In response to DNA damage,
activated ATM phosphorylates p53 directly on Ser15 and indi-
rectly through Chk2 on Ser20, causing cell cycle arrest or cell
death (23–25). In addition to acting as a sensor of DNA dam-
FIG. 4. ARK5 mediates Akt-induced cell survival signaling. A,
HepG2 cells transiently transfected with () or without () ARK5,
dominant active Akt (DA-Akt), dominant negative Akt (DN-Akt),
ARK5-deletion mutant (ARK(APM)) and/or ARK5-point mutant
(ARK(S600A)) were subjected to glucose starvation for 24 h. Ratio of cell
death induction is shown as means of three experiments, and the bars
represent S.E. value. B, H/ARK cells transiently transfected with or
without DA-Akt or DN-Akt were subjected to glucose starvation in the
presence or absence of LY294002 (20 M) for 24 h.
FIG. 5. ARK5-induced ATM activation. A, schematic model of
phosphorylation site by AMPK or Akt was indicated by arrowhead on
ATM sequence. B, P/ATM cells were transfected with () or without ()
ARK5 or ARK5(AS) for 24 h. After transfection, in vivo labeling of 32P
was performed, and cells were incubated in media with or without
glucose for 1 h. His-ATM was collected with nickel-agarose and phos-
phorylated ATM (pATM; 32P-autoradiography) and total ATM (tATM;
Western blotting of His-ATM with anti-human ATM antibody) were
detected. C, His-ATM (2 g) was reacted with or without ARK5 (2 g)
in the presence or absence of active Akt1 (act.Akt1; 2 g). D, ATM
kinase assay was performed with full-length recombinant protein of
human p53 in the presence or absence of His-ATM (2 g) and/or ARK5
(2 g). E, HepG2 cells transiently transfected with () or without ()
ARK5(AS). After 24 h, cells were subjected to medium with () or
without () glucose for 1 h, and then Western blotting using antibodies
for p53 and actin was performed.
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age, it has been suggested that ATM is also a sensor of oxida-
tive stress (31, 32). Evidence for increased oxidative stress in
A-T cells and in ATM gene-disrupted mice supports this sug-
gestion (33, 34). Nutrient starvation induces necrotic cell death
in HepG2 cells, and a comet assay revealed that necrotic cell
death is not due to DNA double strand break (data not shown).
Recently, we found ATM-induced phosphorylation and accumu-
lation of p53 following p21 up-regulation and cell cycle arrest at
the G1 phase in HepG2 cells during glucose starvation.
2 Our
current observations that ARK5 phosphorylated ATM in vitro
and in vivo in response to glucose starvation together with an
involvement of the ATM/p53 pathway in maintaining cell sur-
vival during glucose deprivation provide additional support for
a more general role for ATM in intracellular signaling. Amino
acid sequence analysis revealed that ATM contained consensus
sequences phosphorylated by AMPK and Akt. Other evidence
of a role for ATM in non-damage signaling has been provided
(35) where insulin activated ATM kinase to phosphorylate 4E-
BPI (PHAS-1), a regulator of protein synthesis. The results
described here are pertinent to that report (Ref. 35) in that we
have demonstrated that insulin treatment activates Akt, which
in turn activates ARK5, and this may lead to activation of
ATM, which we also showed is a downstream effector of ARK5
under conditions of glucose starvation. The activation of ATM
through this pathway would add an additional pathway to the
scheme proposed after insulin treatment (21).
In the current study, we identified ARK5 as a novel member
of the AMPK family. ARK5 activation is regulated by Akt, and
activated ARK5, in turn, phosphorylated ATM during glucose
starvation. Because phosphorylated ATM induces cell cycle
arrest at the G1 phase via p53 phosphorylation and accumula-
tion (23–25), the present findings are consistent with our pre-
vious notion that the AMPK family is involved in p53 accumu-
lation during glucose starvation (19). ARK5 mRNA expression
in human normal tissue was observed in the heart, brain,
skeletal muscle, kidney, and ovary, but not in the liver, pan-
creas, lung and intestine (official data of KIAA0537 on the
KAZUSA DNA Research Institute homepage); however, pro-
tein and mRNA expression of ARK5 was observed in some
tumor cell lines derived from hepatoma and pancreatic cancer,
suggesting a possible involvement of ARK5 in tumorigenesis.
On the basis of our current results, we propose here that ARK5
plays a key role in the tumor tolerance to nutrient starvation
related to tumor malignancy. Therefore, ARK5 is a new target
for cancer therapy.
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